Update shared on 28 Nov 2025
Fair value Decreased 5.90%Analysts have revised their price target for Beauty Farm Medical and Health Industry downward from ¥38.18 to ¥35.92. They cite higher projected revenue growth and a slightly improved profit margin, along with a modest increase in the discount rate and a reduced future price-earnings multiple.
What's in the News
- A Special or Extraordinary Shareholders Meeting is scheduled for December 5, 2025, at 09:30 China Standard Time (Key Developments)
- The meeting will take place at the Shanghai meeting room, 12th floor, Raffles East Office Tower, No. 1089 Dongdaming Road, Hongkou District, Shanghai, China (Key Developments)
Valuation Changes
- Fair Value Estimate decreased from HK$38.18 to HK$35.92
- Discount Rate has risen slightly from 7.43% to 7.45%
- Revenue Growth Projection increased from 9.67% to 11.96%
- Net Profit Margin improved marginally from 11.75% to 11.87%
- Future P/E Multiple reduced from 21.0x to 19.8x
Disclaimer
AnalystConsensusTarget is a tool utilizing a Large Language Model (LLM) that ingests data on consensus price targets, forecasted revenue and earnings figures, as well as the transcripts of earnings calls to produce qualitative analysis. The narratives produced by AnalystConsensusTarget are general in nature and are based solely on analyst data and publicly-available material published by the respective companies. These scenarios are not indicative of the company's future performance and are exploratory in nature. Simply Wall St has no position in the company(s) mentioned. Simply Wall St may provide the securities issuer or related entities with website advertising services for a fee, on an arm's length basis. These relationships have no impact on the way we conduct our business, the content we host, or how our content is served to users. The price targets and estimates used are consensus data, and do not constitute a recommendation to buy or sell any stock, and they do not take account of your objectives, or your financial situation. Note that AnalystConsensusTarget's analysis may not factor in the latest price-sensitive company announcements or qualitative material.